Sonoma Pharmaceuticals (SNOA) Misses Q3 EPS by 43c Feb 10, 2026 04:45PM
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results Feb 10, 2026 04:10PM
Sonoma Pharmaceuticals appoints new board member and executive Jan 28, 2026 04:16PM
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development Jan 28, 2026 04:15PM
National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced Nov 13, 2025 08:30AM
View Older Stories

Nov 6, 2025 04:01PM Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf
Nov 4, 2025 11:41PM Sonoma Pharmaceuticals (SNOA) reports Q2 result
Nov 4, 2025 08:56AM Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results
Oct 14, 2025 08:30AM Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals
Oct 7, 2025 08:32AM Sonoma Pharmaceuticals registers facility under FDA cosmetic rules
Oct 7, 2025 08:30AM Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA
Sep 25, 2025 04:01PM Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Aug 26, 2025 08:30AM National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced
Aug 13, 2025 04:01PM Sonoma Pharmaceuticals launches diaper rash product in 3,600 Walmart stores
Aug 13, 2025 04:01PM Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains
Jun 17, 2025 04:10PM Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results
Apr 23, 2025 08:18AM Sonoma Pharmaceuticals (SNOA) Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain
Apr 22, 2025 04:01PM Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain
Mar 10, 2025 04:04PM Sonoma Pharmaceuticals (SNOA) Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by MHRA
Mar 10, 2025 04:01PM Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)
Feb 25, 2025 04:01PM Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando
Feb 6, 2025 04:31PM Sonoma Pharmaceuticals (SNOA) Tops Q3 EPS by 6c
Feb 5, 2025 04:05PM Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results
Jan 30, 2025 05:24PM Sonoma Pharmaceuticals secures new supply agreement
Dec 5, 2024 08:30AM Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
Nov 21, 2024 04:06PM Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
Nov 11, 2024 04:31PM Sonoma Pharmaceuticals (SNOA) Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
Nov 11, 2024 04:20PM Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
Nov 8, 2024 06:19AM Sonoma Pharmaceuticals, Inc. (SNOA) Misses Q2 EPS by 54c
Nov 7, 2024 08:45AM Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results
Oct 31, 2024 04:01PM Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf
Oct 22, 2024 08:35AM Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada
Oct 21, 2024 04:01PM Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences
Sep 19, 2024 08:34AM Sonoma Pharmaceuticals (SNOA) Regains Nasdaq Compliance
Sep 19, 2024 08:30AM Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Sep 17, 2024 08:54AM Sonoma Pharmaceuticals (SNOA) Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn-Based Solution
Sep 17, 2024 08:30AM Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution
Sep 11, 2024 08:34AM Sonoma Pharmaceuticals (SNOA) and EMC Pharma Collaborate to Co-market an Expanded Eye Care Product Line
Sep 11, 2024 08:30AM Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line
Aug 28, 2024 06:17AM Sonoma Pharmaceuticals (SNOA) Announces 1:20 Reverse Share Split
Aug 28, 2024 06:10AM Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock
Aug 26, 2024 08:30AM Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff
Aug 21, 2024 08:51AM Sonoma Pharmaceuticals (SNOA) Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States
Aug 21, 2024 08:45AM Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States
Aug 8, 2024 04:10PM Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results
Jul 9, 2024 07:30AM Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine
Jun 17, 2024 05:00PM Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results
View Older Stories